MedPath
HSA Approval

CLAMOVID 625 TABLET 625 mg

SIN12026P

CLAMOVID 625 TABLET 625 mg

CLAMOVID 625 TABLET 625 mg

July 17, 2002

GOLDPLUS UNIVERSAL PTE LTD

GOLDPLUS UNIVERSAL PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGOLDPLUS UNIVERSAL PTE LTD
Licence HolderGOLDPLUS UNIVERSAL PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

ORAL

Medical Information

J01CR02

amoxicillin and beta-lactamase inhibitor

Manufacturer Information

GOLDPLUS UNIVERSAL PTE LTD

Bilim Ilac Sanayi Ve Ticaret Anonim Sirketi

Active Ingredients

AMOXYCILLIN TRIHYDRATE

500 mg

Amoxicillin

CLAVULANATE POTASSIUM

125 mg

Clavulanic acid

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

CLAMOVID 625 TABLET 625 mg - HSA Approval | MedPath